General Information

Biocon Limited is a fully integrated biopharmaceutical company focused on biopharmaceuticals, custom research and clinical research.

Subsidiary Companies:

Syngene International Limited is a custom research organisation offering synthetic chemistry and molecular biology services for early stage drug discovery and development.

Clinigene International Limited is a clinical research organisation offering Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors.

Biocon Biopharmaceuticals Private Limited (BBPL) began as a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines. In March 2010, Biocon acquired CIMAB’s 49% stake and BBPL became a 100% subsidiary.

Biocon research Limited (BRL) is a wholly owned subsidiary set up to undertake discovery and development research work in biologics, antibody molecules and proteins. BRL continues to progress the development activity on the monoclonal antibody program in joint collaboration with Mylan. Being a research driven enterprise, the Company is in the initial stage of operations and has enlarged its scope to other challenging research projects during the year.

NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi. Incorporated in January 2008, NeoBiocon is a 50:50 joint venture with Dr. B.R.Shetty, Managing Director of NeoPharma, Abu Dhabi.

Biocon SA is a wholly owned subsidiary in Switzerland primarily engaged in the development and commercialization of biopharmaceuticals across the globe. Clinical Development of Insulin is currently ongoing in the European region.

Biocon SDN. BHD. is a wholly owned subsidiary in Malaysia to set up a state of the art manufacturing facility at BioXcell a biotechnology park promoted by the Government of Malaysia. In the first phase of capital outlay, the Company envisages an investment of US$ 161 million and expects the facility to go on stream by year 2015.

Intellectual Profile of 6000+ Personnel

Biocon, Syngene and Clinigene together employ over 6000 qualified personnel - from biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, HR generalists to general administrators. 5% of our employees have PhD degrees, 48% have master's degree in science or management and the remaining are graduates with bachelor's degree in science, commerce or arts. 13% of Biocon employees are women (across the group). The annualized employee attrition for Q3 FY 2011-12 is 25%. The average age of an employee is 30 years.

Milestones

- Biocon is India's first biotechnology company, established
  in 1978

- Biocon is India's first biotechnology company to export
  microbial enzymes to USA and Europe

- Biocon is the first biotechnology company to receive ISO
  9001 certification in India

- Syngene, a Biocon subsidiary, is India's first custom
  research company in drug discovery

- Biocon is the first Indian company to be approved by
  US FDA for the manufacture of lovastatin, a
  cholesterol-lowering molecule

- Biocon's proprietary bioreactor, the PlaFractor™, receives a   US patent

- Biocon's subsidiary, Clinigene, has India's first CAP
  (College of American Pathologists) accredited clinical
  research laboratory, setting the benchmark for
  laboratories in India

- Biocon is awarded the Biotech Product and Process
  Development and Commercialisation Award, 2001 by
  the Department of Biotechnology, Ministry of Science
  and Technology, Government of India

- Syngene is awarded the Certificate of Excellence for
  Export Achievement by the Government of India, for
  two consecutive years 2002-2003

- Biocon is the first company, globally to manufacture
  human insulin, INSUGEN^®, using a Pichia expression
  system, 2004

- Biocon launches BIOMAb EGFR^® India's first anti-cancer,   therapeutic Monoclonal Antibody-based drug for treating solid   tumors of epithelial origin, such as head & neck cancers, 2006

- Biocon divests its enzymes division to Novozymes, focuses   on biopharmaceuticals, 2007

- Syngene receives "BioServices Company of the Year",
  BioSpectrum Awards, 2007

- Biocon's BIOMAb EGFR^® wins "Product of the Year",
  BioSpectrum Awards, 2007

- Biocon acquires a 78% stake in German pharmaceutical   company, AxiCorp GmbH for a consideration of €30
  Million, 2008

- Biocon launches a Safety Device in the form of pre-filled   syringes for two of its life saving products, GCSF (granulocyte-  colony stimulating factor) and EPO (Erythropoietin) in   collaboration with Safety Syringes Inc. ERYPRO Safe™ and   NUFIL Safe™ are the first two drugs that will marketed using   this novel device with other injectable products to follow in the   future, 2008

- Biocon and Abraxis Bioscience launch ABRAXANE in India for   treatment of Breast Cancer, 2008

- Biocon is ranked among the top 20 global biotechnology   companies (Med Ad News), 2008

- Biocon is the 7th largest biotech employer in the world (Med   Ad News), 2008

- Biocon announced the results of an ascending dose study on   its oral insulin drug (IN-105) at the European Association for   the Study of Diabetes (EASD) meeting in Rome, 2008

- NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE   for the treatment of Breast Cancer, 2008

- Biocon's Syngene partners with Sapient Discovery to expand   integrated drug discovery offerings, 2009

- Biocon's Syngene and DuPont Crop Protection Forge Alliance   Partnership, 2009

- Bristol-Myers Squibb and Biocon's Syngene open new R&D   Facility at Biocon Park, 2009

- Biocon launches BASALOG - long lasting basal insulin for Type   1 & Type 2 Diabetics, 2009

- Biocon inks partnership with ISB to launch the Biocon Cell for   Innovation Management, 2009

- Biocon Announces Strategic Collaboration with Mylan to enter   the Global Generic Biologics Market, 2009

- Biocon Limited and Amylin Pharmaceuticals entered into a   Global Development and Commercialization Agreement for a   Novel Peptide Hybrid. The Program will focus on the potential   treatment of diabetes, 2009

- Biocon and HCG group of hospitals join hands to fight against   cervical, 2009

- Biocon explores investment in Malaysia in partnership with   BiotechCorp, 2010

- Biocon and Bayer join hands to create awareness for self   monitoring for diabetics, 2010

- Syngene and Endo Pharmaceuticals, USA  to  jointly discover   and develop novel biological drug molecules to fight cancer,   2010

- Biocon acquires stake of its Cuban partner CIMAB S.A. in their   seven year old JV, Biocon Biopharmaceuticals Pvt. Ltd, 2010

- Biocon and Optimer Pharmaceuticals announce manufacturing   and supply agreement for a novel API, first-in-class anti-   infective (C. difficile), 2010

- Biocon and the Center of Molecular Immunology (CIM), based   in Havana, Cuba strengthen their existing research   partnership by joining forces for an integrated antibody   program in immunology, 2010

- Biocon and Pfizer  announce strategic global agreement for the   worldwide commercialization of Biocon's biosimilar versions of   Insulin and Insulin analog products: Recombinant Human   Insulin, Glargine, Aspart and Lispro, 2010

- Biocon announces a strategic foreign direct investment in   Malaysia with the Malaysian Biotechnology Corporation SdnBhd   BiotechCorp), 2010

- Biocon divests its stake in its German subsidiary, AxiCorp   GmbH, to the existing group of promoter shareholders,   AxiCorp was the licensee for Biocon's biosimilar Insulin and   Glargine in Germany and had the sole responsibility for   commercializing these products. As a consequence of this   divestment, these rights revert to Biocon, 2011

- Biocon launches INSUPen^®, a convenient and affordable   reusable insulin delivery device, 2011

Biopharmaceuticals

Active Pharmaceutical Ingredients (APIs)

- Anti-Diabetic Agents
- Anti-Inflammatory Agents
- Anti-Oxidants
- Cardiovascular Agents
- Anti-Obesity Agents
- Digestive-Aid Enzymes
- Anti-Hypertensive Agents
- Haemostatic Agents
- Hepatoprotective Agents
- Immunosuppressants
- Gastro-Intestinal Agents
- Nutraceuticals

Biologicals

- Insulin & analogs
- Streptokinase
- EPO
- GCSF
- Monoclonal Antibodies

Branded Formulations

Oncology

- BIOMAb EGFR^®
- NUFIL safe^™ (Pre-filled Syringe)
- Abraxane^® for injectable suspension
- Evertor ^™

Nephrology

- ERYPRO^™
- ERYPRO safe^™ (Pre-filled Syringe)
- TACROGRAF^™
- RAPACAN^™
- CYCLOPHIL ME^®
- RENODAPT^®
- RENODAPT^® - S
- CeRACaL^™
- BIOSEV^™
- NARITA^™
- ADVACAN^™

Cardiology

- STATIX^®
- STATIX^®-F
- STATIX^®-EZ
- BESTOR^®
- BESTOR FN^®
- TELMISAT^®
- TELMISAT^®-H
- TELMISAT^®-AM
- ZARGO^®
- ZARGO^®-H
- ACTIBLOK^™-IPR
- ACTIBLOK^™-AM
- BRADIA^™
- CLASPRIN^®
- MYOKINASE^®
- CLOTIDE^®
- DYNALIX^®
- PRASACT^™
- TIROZEST^™

Diabetology

- INSUGEN^® - 30/70 100IU
- INSUGEN^®- 50/50 100 IU
- INSUGEN^®- N 100 IU
- INSUGEN^®- R 100 IU
- INSUGEN^®- 30/70 40 IU
- INSUGEN^®- 50/50 40 IU
- INSUGEN^®- N 40 IU
- INSUGEN^®- R 40 IU
- BASALOG^™ 3ml, 10 ml
- BLISTO^™ 1, 2 & 4
- BLISTO^™-MF 1, 2 & 4
- GABIL^™
- GMAB^™ Plus
- METADOZE-IPR^® 500 & 850
- OLISAT^™ 60 & 120
- PIODART^® 15 & 30
- PIODART^®-MF
- TriGPM^™ 1 & 2
- ZUKER^™-MF

Immunotherapy

- TBIS^®
- PICON^®
- PSORID^™

Comprehensive Care

- CELRIM^™
- CELRIM^™TZ
- BIOPIPER-TZ^™
- PENMER^™
- PENMER^™500
- IMICELUM^™
- MEEZAT^™
- GENPIROME^™
- ENTAVAR^™
- ENTAVAR^™- 600

Dosage Forms

Biocon offers Indian pharmaceutical companies finished dosage formulations in the categories of cardiology, diabetology, nephrology, oncology, Immunotherapy, Comphrehensive Care and other specialised therapeutic segments. We provide formulations in the form of tablets, capsules, injections, liquid-orals and pellets.

20th KM Hosur Road
Electronics City
Bangalore 560 100
India
Phone: 91 80 2808 2808 / 91 80 4014 4014
Fax: 91 80 2852 3423
Email: contact.us@biocon.com

Overseas Representative Office

New Jersey

Biocon Limited
485 Hwy 1 (S)
Suite B 305
Iselin, NJ 08830
Tel: (732) 636 2950
Fax: (732) 636 2951
Email: abhijit.zutshi@biocon.com

London

Biocon (London) Limited
50, Elm Quay Court
30, Nine Elms Lane
SW8 5DF, London
Phone : +44 2078199788
Fax : +44 2074502980
Mobile : +44 7515962466
Email: nehal.vora@biocon.com

Abu Dhabi

NeoBiocon
P.O. Box 72900
Abu Dhabi
United Arab Emirates
Phone: +971 -2- 6585 990
Fax: +971 -2- 6321 626
Email: sumit.bhanot@biocon.com

Dubai

NeoBiocon
Dubai HealthCare City
P.O. Box 505176
Dubai
United Arab Emirates
Phone: +971 -4- 454 1079
Fax: +971 -4- 454 1125
Mobile: +971 50 5826489
Email: sumit.bhanot@biocon.com

Human Resources

For careers at Biocon, please contact us at:
Phone: 91 80 2808 2808 / 91 80 4014 4014
Email: human.resources@biocon.com

Licensing/ Collaboration Opportunities

To submit licensing/collaboration opportunities
enquiries, please contact:
Mr. Sandeep Rao
Vice President - Business Development and Licensing
Phone: 91 80 2808 2070
Email: sandeep.rao@biocon.com

Investor Relations

For investor related queries please contact:
Mr. Kiran Kumar
Company Secretary
Phone: 91 80 2808 2037
Email: investor.relations@biocon.com

Top